Core Viewpoint - aTyr Pharma, Inc. is facing intensified financial and legal pressures following disappointing third-quarter results that missed Wall Street estimates, alongside ongoing securities class action litigation related to misleading information about its drug Efzofitimod [1][5]. Financial Performance - aTyr reported a GAAP EPS loss of -$0.26 for Q3, missing analyst consensus estimates by $0.08 [3]. - The company's revenues were reported at $190,000, indicating a heavy reliance on its clinical pipeline rather than commercial sales [3]. Clinical Developments - Despite the disappointing results from the Phase 3 EFZO-FIT study, aTyr plans to meet with the U.S. FDA in Q1 2026 to discuss the study results and the future of Efzofitimod in treating pulmonary sarcoidosis [4]. - The EFZO-FIT study did not meet its primary endpoint, leading to a significant market reaction with the stock price dropping over 83% in one day, from $6.03 to $1.02 [6]. Legal Issues - The ongoing securities class action litigation alleges that aTyr and its executives provided materially false and misleading information regarding Efzofitimod's efficacy [5]. - The class action period has been expanded to include investors who acquired shares between November 7, 2024, and September 12, 2025, with claims that the company concealed deficiencies in the drug's performance [7]. - Hagens Berman is investigating whether aTyr misled investors about its data and trial design while promoting Efzofitimod's market potential [8].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to misleading statements about the efficacy of its drug Efzofitimod, which led to significant stock price decline [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for aTyr investors affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - Defendants allegedly made positive statements about Efzofitimod while concealing adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in an 83.2% decline in stock price from $6.03 to $1.02 per share in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and financial prospects, which have adversely affected shareholders [1]. Company Summaries Molina Healthcare, Inc. (NYSE: MOH) - Class Period: February 5, 2025 – July 23, 2025 - Allegations include failure to disclose adverse facts about medical cost trend assumptions and a dislocation between premium rates and medical costs, leading to a likely cut in financial guidance for fiscal year 2025 [2]. Marex Group plc (NASDAQ: MRX) - Class Period: May 16, 2024 – August 5, 2025 - Allegations include selling over-the-counter financial instruments to itself and inconsistencies in financial statements, making the financial data unreliable [3]. aTyr Pharma Inc. (NASDAQ: ATYR) - Class Period: November 7, 2024 – September 12, 2025 - Allegations include misleading statements regarding the study design for EFZO-FIT and the failure to meet primary endpoints, which misrepresented the company's prospects [4]. WPP plc (NYSE: WPP) - Class Period: February 27, 2025 – July 8, 2025 - Allegations include the media arm's inability to handle macroeconomic challenges and loss of market share, rendering positive statements about the company's operations misleading [6].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant drop in stock price after disappointing study results were announced [3][4]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma made overwhelmingly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly regarding the drug's ability to allow patients to taper off steroids completely [3]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [3]. Group 2: Class Action Details - Shareholders who purchased aTyr shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline set for December 8, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - The Gross Law Firm, which is leading the class action, emphasizes its commitment to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1]. Summary by Sections Allegations - The complaint alleges that aTyr Pharma provided overwhelmingly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly its ability to allow patients to taper steroid usage completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically in the change from baseline in mean daily OSC dose at week 48 [1]. Stock Price Impact - Following the announcement of the disappointing study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Class Action Details - Shareholders who purchased shares of aTyr during the class period from November 7, 2024, to September 12, 2025, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1][2]. - The deadline for shareholders to register for the class action is December 8, 2025, and there is no cost or obligation to participate [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of aTyr Pharma, Inc. during the specified class period of the upcoming lead plaintiff deadline on December 8, 2025, for a class action lawsuit related to misleading statements about the drug Efzofitimod [1][5]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise and reputation in handling such cases [4]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma provided misleading statements regarding the efficacy of Efzofitimod, particularly concerning its ability to allow patients to taper off steroid usage completely [5]. - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading nature of the statements made by the company [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. related to misleading statements about the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [3][6]. Group 1: Legal Action and Investor Rights - Investors who purchased aTyr securities between January 16, 2025, and September 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [2][3]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [3][8]. Group 2: Allegations Against aTyr Pharma - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements regarding Efzofitimod's efficacy, particularly its ability to allow patients to taper off steroids completely [6]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [7]. Group 3: Market Impact - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the drug Efzofitimod, which led to significant financial losses for investors [1][3]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to contact them regarding their legal rights [1]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [1]. Allegations Against aTyr - The complaint alleges that aTyr and its executives made false and misleading statements about the efficacy of Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [3]. - The company is accused of providing overly positive statements while concealing material adverse facts, which resulted in shareholders purchasing securities at artificially inflated prices [3]. Clinical Study Results - In the EFZO-FIT study, efzofitimod did not show a significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [4]. - Complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [4]. - Following the release of these results, aTyr's stock price plummeted by 83.25%, dropping from $6.03 on September 12 to $1.01 on September 15 [4].

Accessibility StatementSkip Navigation NEW YORK, Nov. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between November 7, 2024 and September 12, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1][2]. Summary by Sections Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly regarding the drug's ability to allow patients to taper off steroids completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a drastic stock price decline from $6.03 to $1.02 per share, an 83.2% drop in one day [1]. Class Action Details - Shareholders who purchased shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].